NSE
Aurobindo Pharma LimitedAUROPHARMA
Aurobindo Pharma is a major generics and API company.
| Key products | US & Europe generics, APIs, injectables, biosimilars. |
|---|---|
| Geography | US, Europe, India. |
| Competitors | Sun Pharma, Cipla, Dr Reddy's. |
AI-generated overview — verify before relying on it.
Net institutional flow
No institutional deals
Institutional buyers
0 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
—
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ALKEM | +₹1,013.7 Cr | 13 | — | — | -2 | 6 |
| 2 | AUROPHARMAThis | — | — | — | — | — | — |
| 3 | CIPLA | — | — | — | — | +19 | 44 |
| 4 | DRREDDY | — | — | — | — | +20 | 46 |
| 5 | SUNPHARMA | — | — | — | — | +15 | 45 |
| 6 | TORNTPHARM | — | — | — | — | — | — |
| 7 | LUPIN | — | — | — | — | — | — |
| 8 | ZYDUSLIFE | — | — | 1 | +1 | — | — |
| 9 | MANKIND | — | — | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
SWOT
Strengths
- • Strong presence in the US market with a large portfolio of generic products
- • Diversified revenue streams from both API and finished dosage form (FDF) segments
- • Significant investments in research and development to enhance pipeline and capabilities
- • Established partnerships with major pharmaceutical companies for co-development and co-marketing
Weaknesses
- • Dependence on a few key products, including biosimilars, which can be subject to regulatory risks
- • Competition from low-cost generics in the US market, impacting margins
- • Limited presence in emerging markets, such as China and India, compared to peers
- • Regulatory challenges in Europe due to Brexit and changing regulatory landscapes
Opportunities
- • Growing demand for biosimilars in emerging markets, presenting a significant growth opportunity
- • Increasing focus on digital healthcare and telemedicine, creating potential for API sales
- • Expansion into new geographies, such as Africa and Latin America, to diversify revenue streams
- • Partnerships with biotechnology companies to develop innovative products
Threats
- • Intensifying competition from generic and biosimilar manufacturers in the US market
- • Regulatory changes in key markets, such as the EU's new pharmaceutical strategy
- • Increasing costs associated with research and development, particularly for complex molecules
- • Global economic uncertainty and trade tensions impacting demand for pharmaceuticals
AI-generated from our data — verify before relying on it.
- 2026-06-12FilingAurobindo Pharma Limited has informed the Exchange about General UpdatesGeneral
- 2026-06-11FilingAurobindo Pharma Limited has informed the Exchange about Copy of Newspaper PublicationCompliance
- 2026-06-09FilingAurobindo Pharma Limited has informed the Exchange about Schedule of meetInvestor Call
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 2
- 1
- 2
No bulk/block deals for AUROPHARMA in this window.
Results & transcripts
Financial results
None yet.
News & chatter on AUROPHARMA
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.